Filing Flows › Monte Rosa Therapeutics (GLUE) › Q1 2026
Monte Rosa Therapeutics (GLUE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Monte Rosa Therapeutics (GLUE) reported revenue of $4.2M for the first quarter 2026 (Q1 2026), -95% from a year earlier and +51% from the quarter before.
Monte Rosa Therapeutics, Q1 2026: revenue $4.2M (-95% year over year), net loss $44.5M, operating cash flow −$37.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.2M | +51% | -95% |
| Operating profit | −$50.0M | — | -214% |
| Net earnings | −$44.5M | — | -195% |
| Operating cash flow | −$37.4M | — | — |
What changed
Revenue was $4.2M in Q1 2026, down 95% year over year and up 51% from the previous quarter.
Operating costs exceeded revenue by $50.0M, an operating margin of -1188.5%. Total costs grew 33% against a revenue fall of 95%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $44.5M, narrower than the previous quarter's $46.1M loss.
Operating cash flow was −$37.4M. Non-cash charges added back $2.7M of depreciation and amortization and $5.9M of share-based compensation. Capital expenditures of $1.9M exceeded it, leaving free cash flow of −$39.2M.
Questions
What was Monte Rosa Therapeutics' revenue in the first quarter 2026?
Monte Rosa Therapeutics (GLUE) reported revenue of $4.2M for the first quarter 2026 (Q1 2026), -95% from a year earlier and +51% from the quarter before.